Anti-inflammatory mediators' activity

Anti-inflammatory mediators' activity is a functional term describing the combined physiological effects of various endogenous molecules—such as interleukin-10 (IL-10), transforming growth factor-beta (TGF-beta), and specialized pro-resolving mediators (SPMs)—that function to attenuate inflammatory responses and facilitate tissue repair [1][2]. This activity is not a single molecular target, such as a specific receptor or enzyme, but rather a collective physiological state or pharmacological endpoint representing the resolution phase of inflammation [3]. In clinical practice, numerous therapeutic agents, including glucocorticoids and cytokine-based therapies, aim to augment this activity to treat chronic inflammatory conditions like rheumatoid arthritis or inflammatory bowel disease [4]. Because this term encompasses a vast network of distinct pathways rather than a specific protein, it is characterized as a biological process or pharmacological category rather than a discrete therapeutic target [5]. Proper regulation of this activity is essential to prevent tissue damage while ensuring the host can still mount an effective defense against pathogens.

Other names

Anti-inflammatory responseImmune resolution activityCounter-inflammatory signalingEndogenous anti-inflammatory mechanisms

Promotion of anti-inflammatory signaling and suppression of pro-inflammatory cytokine production through the activation of specialized receptors or transcriptional regulation.